Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer

NCT04887805 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Advanced Pancreatic Ductal Adenocarcinoma
Stage II Pancreatic Cancer AJCC v8
Stage IIA Pancreatic Cancer AJCC v8
Stage IIB Pancreatic Cancer AJCC v8
Stage III Pancreatic Cancer AJCC v8
Stage IV Pancreatic Cancer AJCC v8
Unresectable Pancreatic Ductal Adenocarcinoma

Interventions

DRUG: Lenvatinib Mesylate
BIOLOGICAL: Pembrolizumab

Sponsor

City of Hope Medical Center

Collaborators

[object Object]